Advanced Technology Radiation Therapy with Dose Painting: Opportunities for Outcome Improvement for Management of Lymphoma
Main Article Content
Radiation therapy remains important in the modern management of both Hodgkin and non-Hodgkin lymphoma. Radiation is applied as both consolidation therapy post chemotherapy and primary therapy for selected limited volume clinically favorable histology. Application of modern therapy techniques permits more sparing of normal tissue in all anatomical locations. Modern image guidance permits both security in daily patient treatment set up and permits strategic titration of the planning target volume to further spare normal tissue. Four-dimensional planning makes certain targets are fully treated in all phases of the breathing cycle. Dose painting with altered fractionation permits identification of low, intermediate, and high-risk areas of concern and treat each in a single plan with multiple fractionation schemes saving both time of treatment and cost of therapy. In this paper we present multiple examples of the application of modern therapy techniques in lymphoma management and demonstrate advantages of modern radiation in several anatomical regions.
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
2. FitzGerald TJ, Urie M, Ulin K, et al. Processes for quality improvements in radiation oncology clinical trials. Int J Radiat Oncol Biol Phys. 2008;71(1 Suppl):S76-9.
3. FitzGerald TJ, Followill D, Galvin J et al. Restructure of clinical trial system addresses evolving needs. ASTRO News. Published online Winter 2014:36.
4. Mendenhall NP, Meyer J, Williams J, et al. The impact of central quality assurance review prior to radiation therapy on protocol compliance: POG 9426, a trial in pediatric Hodgkin’s disease. Blood. 2005;106(11):753-753.
5. Fitzgerald TJ, Bishop-Jodoin M, Bosch WR, et al. Future vision for the quality assurance of oncology clinical trials. Front Oncol. 2013;3:31.
6. Dharmarajan KV, Friedman DL, Schwartz CL, et al. Patterns of relapse from a phase 3 Study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the Children’s Oncology Group. Int J Radiat Oncol Biol Phys. 2015;92(1):60-66.
7. Dharmarajan KV, Friedman DL, FitzGerald TJ, et al. Radiotherapy quality assurance report from children’s oncology group AHOD0031. Int J Radiat Oncol Biol Phys. 2015;91(5):1065-1071.
8. Fitzgerald TJ, Bishop-Jodoin M, Cicchetti MG, et al. Quality of radiotherapy reporting in randomized controlled trials of Hodgkin’s lymphoma and non-Hodgkin’s lymphoma: in regard to Bekelman and Yahalom (Int J Radiat Oncol Biol Phys 2009;73:492-498). Int J Radiat Oncol Biol Phys. 2010;77(1):315-316.
9. FitzGerald TJ. What we have learned: the impact of quality from a clinical trials perspective. Semin Radiat Oncol. 2012;22(1):18-28.
10. Gong YUT, Yu J, Pang D, Zhen H, Galvin J, Xiao Y. Automated extraction of dose/volume statistics for radiotherapy-treatment-plan evaluation in clinical-trial quality assurance. Front Oncol. 2016;6:47.
11. Followill DS, Urie M, Galvin JM, Ulin K, Xiao Y, Fitzgerald TJ. Credentialing for participation in clinical trials. Front Oncol. 2012;2:198.
12. FitzGerald TJ, Bishop-Jodoin M. Hodgkin lymphoma: Differences in treatment between Europe and the United States/north America: Evolving trends in protocol therapy. Clin Med Insights Oncol. 2018;12:1179554918754885.
13. Hutchings M. FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy? Hematol Oncol Clin North Am. 2014;28(1):87-103.
14. Kelly KM. Hodgkin lymphoma in children and adolescents: improving the therapeutic index. Hematology Am Soc Hematol Educ Program. 2015;2015(1):514-521.
15. Press OW, Li H, Schöder H, et al. US Intergroup trial of response-adapted therapy for stage III to IV Hodgkin Lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816. J Clin Oncol. 2016;34(17):2020-2027.
16. Pieters RS, Wagner H, Baker S, et al. The impact of protocol assignment for older adolescents with hodgkin lymphoma. Front Oncol. 2014;4:317.
17. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791-1799.
18. Fairchild A, Straube W, Laurie F, Followill D. Does quality of radiation therapy predict outcomes of multicenter cooperative group trials? A literature review. Int J Radiat Oncol Biol Phys. 2013;87(2):246-260.
19. Bekelman JE, Deye JA, Vikram B, et al. Redesigning radiotherapy quality assurance: Opportunities to develop an efficient, evidence-based system to support clinical trials—report of the national cancer institute work group on radiotherapy quality assurance. Int J Radiat Oncol Biol Phys. 2012;83(3):782-790.
20. Chen L, Bai S, Li G, et al. Accuracy of real-time respiratory motion tracking and time delay of gating radiotherapy based on optical surface imaging technique. Radiat Oncol. 2020;15(1):170.
21. Wagner TH, Meeks SL, Bova FJ, et al. Optical tracking technology in stereotactic radiation therapy. Med Dosim. 2007;32(2):111-120.